<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03135275</url>
  </required_header>
  <id_info>
    <org_study_id>MULTISTARS_USZ</org_study_id>
    <nct_id>NCT03135275</nct_id>
  </id_info>
  <brief_title>MULTivessel Immediate Versus STAged RevaScularization in Acute Myocardial Infarction -The MULTISTARS AMI Trial</brief_title>
  <acronym>MULTISTARS AMI</acronym>
  <official_title>MULTivessel Immediate Versus STAged RevaScularization in Acute Myocardial Infarction - The MULTISTARS AMI Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Zurich</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the trial is to compare, in patients presenting with ST segment
      elevation myocardial infarction (STEMI) and multi-vessel disease (MVD), the safety and
      efficacy of immediate complete revascularization of all significant coronary lesions versus
      culprit vessel only revascularization and staged percutaneous coronary intervention (PCI) of
      all significant coronary lesions (within 19 to 45 days), in a non-inferiority trial using a
      third generation, biodegradable-polymer, everolimus-eluting stent.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An investigator-initiated, randomized, multicenter, two-arm, open-label study of consecutive
      patients presenting with STEMI and MVD in stable hemodynamic conditions, undergoing after
      successful PCI of the culprit lesion either (1:1 randomization) immediate revascularization
      of all additional target lesions during the index procedure or staged PCI of all additional
      target lesions (within 19 to 45 days) using the Boston Scientific Synergy™ stent.

      The goal of this trial is to compare two treatment strategies that are currently performed in
      clinical practice: immediate complete revascularization versus staged complete
      revascularization in patients with STEMI and MVD.

      Patients randomized to immediate complete revascularization will have treated during the
      index procedure, after revascularization of the culprit lesion, all significant non-culprit
      coronary lesions.

      Patients randomized to staged complete revascularization will have treated during the index
      procedure only the culprit lesion, and they will be hospitalized after 19-45 days for
      complete revascularization of all significant non-culprit coronary lesions.

      For both groups, lesion are considered significant when causing a ≥70% diameter stenosis by
      visual estimation in at least two projections on the coronary angiogram.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2017</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary outcome measure is a composite of all-cause death, non-fatal myocardial infarction, unplanned ischemia-driven revascularization, hospitalization for heart failure, and stroke at 1 year</measure>
    <time_frame>1-year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>all-cause death</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>non-fatal myocardial infarction</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>unplanned ischemia-driven revascularizations</measure>
    <time_frame>1-year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hospitalization for heart failure</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac death</measure>
    <time_frame>1-year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac death or myocardial infarction</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause death or myocardial infarction</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent thrombosis</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dialysis or acute renal insufficiency</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding event (BARC definition)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>non-cardiovascular death</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular death</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedural success</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (EQ-5D questionnaire)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Lesion Revascularization (TLR)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Vessel Revascularization (TVR)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>composite of all-cause death, non-fatal MI, unplanned ischemia-driven revascularization, hospitalization for heart failure, and stroke</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>composite of all-cause death, non-fatal MI, unplanned ischemia-driven revascularization, hospitalization for heart failure, and stroke</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Cost-effectiveness analysis</measure>
    <time_frame>1 year</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">840</enrollment>
  <condition>ST-elevation Myocardial Infarction</condition>
  <condition>Multivessel Coronary Disease</condition>
  <arm_group>
    <arm_group_label>Staged complete PCI</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients randomized to staged complete PCI will have treated during the index admission only the culprit lesion and they will be hospitalized after 19-45 days, to complete the coronary revascularization on the other significant coronary lesions. All the revascularizations will be performed with Synergy™ stent.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Immediate complete PCI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients randomized to immediate complete PCI will have treated immediately after the revascularization of the culprit lesion during the index procedure, the other significant coronary stenosis. All the revascularizations will be performed with Synergy™ stent.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Staged complete PCI</intervention_name>
    <description>During the index procedure, patients will have treated with primary PCI the culprit lesion only. Patients will be hospitalized again after 19-45 days to undergo PCI of ther other significant coronary lesions. All the revascularizations will be performed with Synergy™ stent.</description>
    <arm_group_label>Staged complete PCI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Immediate complete PCI</intervention_name>
    <description>During the index procedure, patients will have treated with primary PCI the culprit lesion, as well as all the other significant coronary lesions. All the revascularizations will be performed with Synergy™ stent.</description>
    <arm_group_label>Immediate complete PCI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Synergy™ stent</intervention_name>
    <description>Bioabsorbable Polymer Drug-Eluting Stent</description>
    <arm_group_label>Immediate complete PCI</arm_group_label>
    <arm_group_label>Staged complete PCI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 years

          -  Spontaneous acute STEMI (patients presenting within 24 hours of symptom onset)

          -  Suitability for PCI from femoral or radial access

          -  Coronary anatomy suitable for complete coronary revascularization with Synergy® stent
             implantation

          -  Identifiable culprit lesion/artery

          -  At least one non-culprit coronary stenosis ≥ 70% in at least two projections, in a
             vessel with a lumen diameter ≥2.25 - ≤5.75 mm, other than the culprit artery

          -  TIMI Flow 3 or TIMI flow 2 after revascularization of the culprit artery

          -  Stable hemodynamics at the end of the culprit vessel revascularization

        Exclusion Criteria:

          -  Inability to give informed consent

          -  Cardiogenic shock

          -  Prolonged resuscitation &gt;10 min

          -  General unsuitability for PCI

          -  Need for emergency CABG

          -  Previous CABG

          -  Planned hybrid revascularization

          -  Coronary artery dissection

          -  Stent thrombosis

          -  Instent restenosis

          -  Previous documented allergic reaction to everolimus or to any stent material

          -  Severe mechanical complication of acute myocardial infarction

          -  Pre-existing severe renal failure (eGFR &lt;30 mL/min) or dialysis

          -  Chronic total occlusion of a major coronary artery

          -  Left main stem stenosis ≥50% or left main stem equivalent (ostial left anterior
             descending and ostial circumflex stenosis ≥70%)

          -  panned coronary, cerebrovascular, or peripheral arterial revascularization

          -  Planned cardiac or major surgery

          -  Any contraindications for dual antiplatelet therapy with aspirin and a P2Y12 Inhibitor
             for at least 90 days, except for patients on oral anticoagulation

          -  Known pregnancy at the time of inclusion

          -  Participation in another clinical study with an investigational product

          -  Life expectancy &lt;1 year
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Willibald Maier, MD</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <overall_official>
    <last_name>Barbara E. Stähli, MD, eMBA</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <overall_contact>
    <last_name>Barbara E. Stähli, MD, eMBA</last_name>
    <email>barbara.staehli@usz.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Willibald Maier, MD</last_name>
    <email>willibald.maier@usz.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Zürich, Cardiology Department</name>
      <address>
        <city>Zurich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Barbara E Stähli, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <results_reference>
    <citation>Wald DS, Morris JK, Wald NJ, Chase AJ, Edwards RJ, Hughes LO, Berry C, Oldroyd KG; PRAMI Investigators. Randomized trial of preventive angioplasty in myocardial infarction. N Engl J Med. 2013 Sep 19;369(12):1115-23. doi: 10.1056/NEJMoa1305520. Epub 2013 Sep 1.</citation>
    <PMID>23991625</PMID>
  </results_reference>
  <results_reference>
    <citation>Gershlick AH, Khan JN, Kelly DJ, Greenwood JP, Sasikaran T, Curzen N, Blackman DJ, Dalby M, Fairbrother KL, Banya W, Wang D, Flather M, Hetherington SL, Kelion AD, Talwar S, Gunning M, Hall R, Swanton H, McCann GP. Randomized trial of complete versus lesion-only revascularization in patients undergoing primary percutaneous coronary intervention for STEMI and multivessel disease: the CvLPRIT trial. J Am Coll Cardiol. 2015 Mar 17;65(10):963-72. doi: 10.1016/j.jacc.2014.12.038.</citation>
    <PMID>25766941</PMID>
  </results_reference>
  <results_reference>
    <citation>Engstrøm T, Kelbæk H, Helqvist S, Høfsten DE, Kløvgaard L, Holmvang L, Jørgensen E, Pedersen F, Saunamäki K, Clemmensen P, De Backer O, Ravkilde J, Tilsted HH, Villadsen AB, Aarøe J, Jensen SE, Raungaard B, Køber L; DANAMI-3—PRIMULTI Investigators. Complete revascularisation versus treatment of the culprit lesion only in patients with ST-segment elevation myocardial infarction and multivessel disease (DANAMI-3—PRIMULTI): an open-label, randomised controlled trial. Lancet. 2015 Aug 15;386(9994):665-71.</citation>
    <PMID>26347918</PMID>
  </results_reference>
  <results_reference>
    <citation>Kornowski R, Mehran R, Dangas G, Nikolsky E, Assali A, Claessen BE, Gersh BJ, Wong SC, Witzenbichler B, Guagliumi G, Dudek D, Fahy M, Lansky AJ, Stone GW; HORIZONS-AMI Trial Investigators. Prognostic impact of staged versus &quot;one-time&quot; multivessel percutaneous intervention in acute myocardial infarction: analysis from the HORIZONS-AMI (harmonizing outcomes with revascularization and stents in acute myocardial infarction) trial. J Am Coll Cardiol. 2011 Aug 9;58(7):704-11. doi: 10.1016/j.jacc.2011.02.071.</citation>
    <PMID>21816305</PMID>
  </results_reference>
  <results_reference>
    <citation>Cavender MA, Milford-Beland S, Roe MT, Peterson ED, Weintraub WS, Rao SV. Prevalence, predictors, and in-hospital outcomes of non-infarct artery intervention during primary percutaneous coronary intervention for ST-segment elevation myocardial infarction (from the National Cardiovascular Data Registry). Am J Cardiol. 2009 Aug 15;104(4):507-13. doi: 10.1016/j.amjcard.2009.04.016. Epub 2009 Jun 18.</citation>
    <PMID>19660603</PMID>
  </results_reference>
  <results_reference>
    <citation>Widimsky P, Holmes DR Jr. How to treat patients with ST-elevation acute myocardial infarction and multi-vessel disease? Eur Heart J. 2011 Feb;32(4):396-403. doi: 10.1093/eurheartj/ehq410. Epub 2010 Nov 30. Review.</citation>
    <PMID>21118854</PMID>
  </results_reference>
  <results_reference>
    <citation>Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC), Steg PG, James SK, Atar D, Badano LP, Blömstrom-Lundqvist C, Borger MA, Di Mario C, Dickstein K, Ducrocq G, Fernandez-Aviles F, Gershlick AH, Giannuzzi P, Halvorsen S, Huber K, Juni P, Kastrati A, Knuuti J, Lenzen MJ, Mahaffey KW, Valgimigli M, van 't Hof A, Widimsky P, Zahger D. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2012 Oct;33(20):2569-619. doi: 10.1093/eurheartj/ehs215. Epub 2012 Aug 24.</citation>
    <PMID>22922416</PMID>
  </results_reference>
  <results_reference>
    <citation>Authors/Task Force members, Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, Falk V, Filippatos G, Hamm C, Head SJ, Jüni P, Kappetein AP, Kastrati A, Knuuti J, Landmesser U, Laufer G, Neumann FJ, Richter DJ, Schauerte P, Sousa Uva M, Stefanini GG, Taggart DP, Torracca L, Valgimigli M, Wijns W, Witkowski A. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J. 2014 Oct 1;35(37):2541-619. doi: 10.1093/eurheartj/ehu278. Epub 2014 Aug 29.</citation>
    <PMID>25173339</PMID>
  </results_reference>
  <results_reference>
    <citation>Sabaté M, Räber L, Heg D, Brugaletta S, Kelbaek H, Cequier A, Ostojic M, Iñiguez A, Tüller D, Serra A, Baumbach A, von Birgelen C, Hernandez-Antolin R, Roffi M, Mainar V, Valgimigli M, Serruys PW, Jüni P, Windecker S. Comparison of newer-generation drug-eluting with bare-metal stents in patients with acute ST-segment elevation myocardial infarction: a pooled analysis of the EXAMINATION (clinical Evaluation of the Xience-V stent in Acute Myocardial INfArcTION) and COMFORTABLE-AMI (Comparison of Biolimus Eluted From an Erodible Stent Coating With Bare Metal Stents in Acute ST-Elevation Myocardial Infarction) trials. JACC Cardiovasc Interv. 2014 Jan;7(1):55-63. doi: 10.1016/j.jcin.2013.07.012. Epub 2013 Dec 11.</citation>
    <PMID>24332419</PMID>
  </results_reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 10, 2017</study_first_submitted>
  <study_first_submitted_qc>April 25, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 1, 2017</study_first_posted>
  <last_update_submitted>April 2, 2020</last_update_submitted>
  <last_update_submitted_qc>April 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ST-elevation Myocardial Infarction</keyword>
  <keyword>Multivessel coronary disease</keyword>
  <keyword>Immediate complete coronary revascularization</keyword>
  <keyword>Staged complete coronary revascularization</keyword>
  <keyword>Percutaneous coronary intervention</keyword>
  <keyword>Biodegradable-polymer everolimus-eluting stent</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>ST Elevation Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

